Mandate

Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York

Vinge has advised Aprea Therapeutics, Inc. and its subsidiary Aprea Therapeutics AB in connection with its listing on Nasdaq, New York.

The initial public offering price was set to $15 and the biopharmaceutical company sold 6.5 million shares in the IPO to raise $97.75 million. Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing cancer therapeutics.

 
Vinge’s team has primarily consisted of Kristina Ekberg, Charlotte Levin, Maria Schultzberg, Anna Thoms and Stina Bengtsson.

Related

Vinge advises Oral Care in connection with the acquisition of Dutch dental care provider De Tandartsengroep (DTG)

DTG operates 31 clinics and 8 dental laboratories in the Netherlands. Oral Care is a portfolio company of Axcel VI and operates a network of dental clinics in Sweden, Norway and the Netherlands. To support this expansion, Axcel VII is joining Axcel VI as a shareholder in Oral Care.
February 19, 2025

Vinge advises Gotlandsbolaget in connection with off-take agreement regarding biogas

Vinge has advised Rederiaktiebolaget Gotland (Gotlandsbolaget) in connection with the entry into of a strategic off-take agreement, which secures the long-term supply of biogas for the Gotland ferry service traffic.
February 17, 2025

Vinge advises HAKI Safety AB in connection with the acquisition of Trimtec

Trimtec is a Swedish distributor of high-tech precision equipment.
February 14, 2025